Retina research, explained at clinical depth.
Retina Synthesis is a specialist medical show built around retinal disease research and clinical practice. Its conversations move from mechanism to trial design to patient workflow, with particular attention to geographic atrophy, macular disease, diabetic macular edema, ROP, OCT, implants, and intravitreal injection care.
PRESS PLAY
Retina Synthesis is a specialist show about retinal disease research, clinical innovation, and the evidence behind new approaches to care. It is built around long-form conversations rather than news summaries. Dr. Carmen Pugliafido repeatedly guides guests through the biology, trial structure, device design, and clinical workflow behind emerging retina treatments. The center of gravity is medical retina. Geographic atrophy receives sustained attention, including inflammasome-targeted therapy, complement inhibition comparisons, ophthalmic artery angioplasty, and retinal prosthesis work. The conversations are specific. Listeners hear about lesion growth, dosing cohorts, fellow-eye controls, safety signals, photoreceptor loss, bipolar cell stimulation, and what phase three planning might require. The show also spends time on diabetic macular edema and sustained-release fluocinolone implants. Intravitreal injections are treated as both procedure and patient experience, with discussion of anesthesia, antiseptic steps, corneal toxicity, and cooling as a possible comfort strategy. Pediatric retina appears through retinopathy of prematurity, where the focus turns to screening judgment, telemedicine, and when a retina doctor should seek pediatric help. Imaging and computation are another recurring lane. Episodes on home OCT and artificial intelligence look at image equivalence, fluid detection, expert graders, deep learning, and how high-dimensional data may enter ophthalmology practice. The pacing is measured and professional, but it is not generic. Guests often begin with the history of an idea, then move into how the method works and what evidence would make it clinically persuasive. Retina Synthesis is best for listeners comfortable with trial language and ophthalmic terminology. It rewards attention. Its value is the way it connects bench biology, device engineering, diagnostic data, and the practical realities of treating patients with retinal disease.
Made for: Retina specialists, ophthalmologists, vision researchers, medical trainees, and industry listeners who want technical conversations about emerging retinal therapies and diagnostics. It is best for audiences comfortable with clinical trial terms and ophthalmic procedure details.
What sets it apart: The show stays close to the mechanics of retina innovation: why a therapy should work, how a device is delivered, what a trial measured, and where safety concerns remain. It gives specialists room to reason through evidence instead of compressing complex developments into headlines.
Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.
A balloon catheter reaches the retina; you get the safety-study caveat before the victory lap.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A measured review of K8, inflammasome targeting, and early geographic atrophy results.
Geographic atrophy is framed through Jay's explanation of why targeting the inflammasome could behave differently from complement inhibition. He connects the idea to two decades of innate-immunity work, then brings it into the early K8 implant data: across the first two dosing…
Brain science before it becomes a headline.
Structured pharmacy insight for real clinical practice.
Dr.
Dr.
Retina Synthesis host Dr.
Dr.
Dr.
Dr.
An ophthalmologist discusses current diagnosis and treatment of retinopathy of prematurity, emphasizing the importance of direct examination and telemedicine screening.
Dr.
An interview with Professor Pierce Keene about the role of artificial intelligence in managing macular diseases.
Dr.
Dr.
Dr.
An interview with Dr.